pancreatic cancer

[Biomedicine & Pharmacotherapy] Panc-1 and MiaPaCa-2 cells treated chronically with gemcitabine displayed increased transcription and expression of CSC-associated markers.

[Journal of Cellular and Molecular Medicine] Researchers proposed to construct an immune-related prognostic risk model based on immune-related genes MMP14 and INHBA expression that could assess the prognosis of pancreatic cancer patients and identify potential therapeutic targets for pancreatic cancer, to provide new ideas for the treatment of pancreatic cancer.

[Journal of Experimental & Clinical Cancer Research] The authors highlight potential adverse effects of accumulative combination, and further points out future direction in optimization of combination, including targeting post-translational modification of PD-(L)1 and improving precision of treatment.

[Journal of Cachexia Sarcopenia and Muscle] Scientists investigated the effect of pancreatic tumour organoid-derived factors on processes that determine skeletal muscle mass, including the regulation of muscle protein turnover and myogenesis.

[Journal of Magnetic Resonance Imaging] Scientists investigate and summarize the advantages, limitations, and future development of magnetic resonance imaging in the evaluation of neoadjuvant treatment of pancreatic ductal adenocarcinoma.

[Actuate Therapeutics, Inc. (Globe Newswire, Inc.)] Actuate Therapeutics, Inc. announced the opening of a randomized study of elraglusib plus FOLFIRINOX alone or with Losartan for patients with advanced pancreatic cancer in the first-line setting.